Tcr2 Therapeutics Inc logo

Tcr2 Therapeutics Inc Share Price (NASDAQ: TCRR)

▲

-1.48

(-100%)

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 30 May 2023

Check the interactive Tcr2 Therapeutics Inc Stock chart to analyse performance

Tcr2 Therapeutics Inc Key Stats

Check Tcr2 Therapeutics Inc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$1.48
Open
$1.58
Market Capitalization
$62.0M
Today's Volume
$3.9M
Revenue TTM
$0.0
EBITDA
$-129.0M
Earnings Per Share (EPS)
$-3.79
Dividend Yield
0.0%
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-91.46%

Global Institutional Holdings in Tcr2 Therapeutics Inc

  • Name

    Holdings %

  • Mpm Asset Management, LLC

    10.32%

  • TANG CAPITAL MANAGEMENT LLC

    8.66%

  • MPM Oncology Impact Management LP

    8.59%

  • Vanguard Group Inc

    3.74%

  • Newtyn Management LLC

    2.74%

  • Acadian Asset Management LLC

    2.23%

Analyst Recommendation on Tcr2 Therapeutics Inc Stock

Rating
Trend

Hold

    46%Buy

    53%Hold

    0%Sell

Based on 13 Wall street analysts offering stock ratings for Tcr2 Therapeutics Inc(by analysts ranked 0 to 5 stars)

About Tcr2 Therapeutics Inc

TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. Its lead product candidate is gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin-expressing solid tumors, which is in Phase 1/2 clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma and acute myeloid leukemia. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Organization
Tcr2 Therapeutics Inc
Employees
58
CEO
Dr. Garry E. Menzel M.B.A., Ph.D.
Industry
Pharmaceuticals: Major

Important FAQs about investing in TCRR Stock from India :

What is Tcr2 Therapeutics Inc share price today?

Tcr2 Therapeutics Inc share price today is as on at the close of the market. Tcr2 Therapeutics Inc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Tcr2 Therapeutics Inc share?

Tcr2 Therapeutics Inc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Tcr2 Therapeutics Inc stock price today i.e. is closed at , lower by 100% versus the 52 week high.

How to invest in Tcr2 Therapeutics Inc Stock (TCRR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Tcr2 Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Tcr2 Therapeutics Inc Shares .

What is the minimum amount required to buy Tcr2 Therapeutics Inc Stock (TCRR) from India?

Indian investors can start investing in Tcr2 Therapeutics Inc (TCRR) shares with as little as ₹88.097 or $1 (as of September 18, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹880.97 in Tcr2 Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on September 18, 2025). Learn more about fractional shares .

What are the returns that Tcr2 Therapeutics Inc has given to Indian investors in the last 5 years?

Tcr2 Therapeutics Inc stock has given 0.0% share price returns and 19.79% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?